Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia.

No abstract is available for this paper.

• Publication year

  1984

• Venue

  American Journal of Medicine

• Publication date

  1984-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0002-9343(84)90358-9PMID 6385693
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.

  1984cited by this paper
• Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections. A randomized, double-blind trial.

  1984cited by this paper
• [Clinical use of aminoglycosides].

  1983cited by this paper
• Hospital-acquired gram-negative rod pneumonias: an overview.

  1981cited by this paper
• Statistical package for the social sciences (spss)

  1981cited by this paper
• Deaths from nosocomial infections: experience in a university hospital and a community hospital.

  1980cited by this paper
• Aerobic Gram-negative Bronchopneumonias

  1980cited by this paper
• Gram-negative bacteremia: IV. Re-evaluation of clinical features and treatment in 612 patients

  1980cited by this paper
• Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin.

  1980cited by this paper
• Bronchial Secretion Levels of Amikacin

  1979cited by this paper
• The concentration of tobramycin in bronchial secretions.

  1979cited by this paper
• A comparative study of ticarcillin plus tobramycin versus carbenicillin plus gentamicin for the treatment of serious infections due to gram-negative bacilli.

  1978cited by this paper
• Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.

  1978cited by this paper
• Controlled comparison of amikacin and gentamicin.

  1977cited by this paper
• Amikacin therapy of patients with multiply antibiotic-resistant Serratia marcescens infections: development of increasing resistance during therapy.

  1977cited by this paper
• Pulmonary infections.

  1977cited by this paper
• Amikacin in the treatment of gram-negative pneumonia.

  1977cited by this paper
• Penetration of tobramycin into infected extravascular fluids and its therapeutic effectiveness.

  1977cited by this paper
• Clinical evaluation of tobramycin in urinary tract infections.

  1976cited by this paper
• Tobramycin sulfate: a summary of worldwide experience from clinical trials.

  1976cited by this paper
• Pseudomonas bacteremia. Review of 108 cases.

  1976cited by this paper
• Amikacin in the treatment of gram-negative bronchopulmonary infections.

  1976cited by this paper
• Penetration of antimicrobial agents into bronchial secretions.

  1975cited by this paper
• Predictability of blood levels of gentamicin in man.

  1975cited by this paper
• Hospital-acquired pneumonia.

  1974cited by this paper
• Chronic liver disease associated with childhood ulcerative colitis

  1974cited by this paper
• The unpredictability of serum concentrations of gentamicin: pharmacokinetics of gentamicin in patients with normal and abnormal renal function.

  1974cited by this paper
• The effective use of gentamicin in life-threatening sepsis.

  1974cited by this paper
• A rapid chemical assay for gentamicin.

  1972cited by this paper
• Gentamicin therapy in renal failure: a nomogram for dosage.

  1972cited by this paper
• Gentamicin in the treatment of pulmonary infections.

  1969cited by this paper
• Gram-Negative Bacteremia. II. Clinical, Laboratory, and Therapeutic Observations.

  1962cited by this paper

• Renal Impact of a High-Loading Dose of Amikacin in Critically Ill Patients

  2025cites this paper
• A phase I clinical study: evaluation of safety, tolerability, and population pharmacokinetic-pharmacodynamic target attainment analysis of etimicin sulfate among healthy Chinese participants.

  2024cites this paper
• Management of Complex Infections in Hemophagocytic Lymphohistiocytosis in Adults

  2023cites this paper
• Evaluation of Dosing Guidelines for Gentamicin in Neonates and Children

  2023cites this paper
• Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review

  2022cites this paper
• Pharmacokinetic/pharmacodynamic evaluation of tobramycin dosing in critically ill patients: the Hartford nomogram does not fit.

  2021cites this paper
• Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis

  2021cites this paper
• An international survey on aminoglycoside practices in critically ill patients: the AMINO III study

  2021cites this paper
• Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses

  2021cites this paper
• Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria

  2021cites this paper
• Tobramycin Liquid Crystal Nanoparticles Eradicate Cystic Fibrosis-Related Pseudomonas aeruginosa Biofilms.

  2021cites this paper
• Population Pharmacokinetics Analysis of Amikacin Initial Dosing Regimen in Elderly Patients

  2021cites this paper
• Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range

  2021cites this paper
• How to Use Antibiotics in Critically Ill Patients with Sepsis and Septic Shock

  2021cites this paper
• Evaluation of Epithelial Lining Fluid Concentration of Amikacin in Critically Ill Patients With Ventilator-Associated Pneumonia

  2020cites this paper
• Antimicrobial Therapy in Septic Shock Is Conservative During Resuscitation and Maintenance Phases

  2020cites this paper
• S3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge

  2020cites this paper
• PK/PD targets of amikacin and gentamicin in ICU patients.

  2019cites this paper
• Pharmacokinetic Considerations in Neonates

  2019cites this paper
• Rules of anti-infection therapy for sepsis and septic shock

  2019cites this paper
• A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients

  2019cites this paper
• Evaluating the optimal time for amikacin administration with respect to haemodialysis using an in vitro pharmacodynamic simulation against epidemic nosocomial OXA-48 producing Klebsiella pneumoniae ST405 strains.

  2019cites this paper
• Drug Selection and Optimization of Dosage Schedules To Minimize Antimicrobial Resistance

  2019cites this paper
• Sepsis and Septic Shock

  2018cites this paper
• High-dose amikacin for achieving serum target levels in critically ill elderly patients

  2018cites this paper
• Does the Drug Exposure of Aminoglycosides in the Treatment of Tuberculosis relate to Efficacy and Toxicity?

  2018cites this paper
• Effect of hypothermia treatment on gentamicin pharmacokinetics in neonates with hypoxic‐ischaemic encephalopathy: A systematic review and meta‐analysis

  2018cites this paper
• Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling

  2018cites this paper
• New paradigm for rapid achievement of appropriate therapy in special populations: coupling antibiotic dose optimization rapid microbiological methods

  2018cites this paper
• Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?

  2018cites this paper
• Bacterial sepsis

  2017cites this paper
• Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy

  2017cites this paper
• Editorial overview: Use of PK-PD for antibacterial drug development: decreasing risk and paths forward for resistant pathogens.

  2017cites this paper
• The challenge of curbing aminoglycoside resistance: can antimicrobial stewardship programs play a critical role?

  2017cites this paper
• Healthy Mean Volunteers (SD)

  2017cites this paper
• Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing

  2017cites this paper
• [Bacterial sepsis : Diagnostics and calculated antibiotic therapy].

  2017cites this paper
• Bakterielle Sepsis

  2017cites this paper
• Utilisation et optimisation des traitements anti-infectieux chez les patients hospitalisés pour brûlures

  2017cites this paper
• Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

  2017cites this paper
• Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients

  2016cites this paper
• Étude de la nébulisation de deux antibiotiques en ventilation mécanique

  2016cites this paper
• Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy

  2016cites this paper
• INFECCIÓN RESPIRATORIA PEDIÁTRICA: ASPECTOS MICROBIOLÓGICOS, FARMACODINÁMICOS Y CLÍNICOS EN LA ELECCIÓN DE LA TERAPÉUTICA

  2016cites this paper
• Pharmacodynamic Considerations in Critically Ill Patients

  2016cites this paper
• Optimizing beta-lactam antibiotic dosing in critically ill patients: Prolonged infusion versus intermittent bolus administration

  2016cites this paper
• clinical investigations in critical care

  2015cites this paper
• Optimizing Antimicrobial Therapy of Sepsis and Septic Shock: Focus on Antibiotic Combination Therapy

  2015cites this paper
• Use of Selected Antibiotics in the Elderly

  2015cites this paper
• ResearchRevisiting the loading dose of amikacin for patients with severe sepsis and septic shock

  2015cites this paper
• Acute Pneumonia

  2014cites this paper
• Emerging approaches to the treatment of ventilator-associated pneumonia

  2014cites this paper
• Aminoglycoside-Induced Nephrotoxicity

  2014cites this paper
• Laboratory Tests to Direct Antimicrobial Pharmacotherapy

  2014cites this paper
• Laboratory Tests to Direct Antimicrobial

  2014cites this paper
• Outcomes of a new dosage regimen of amikacin based on pharmacokinetic parameters of Korean neonates.

  2014cites this paper
• Gentamicin Pharmacokinetics and Dosing in Neonates with Hypoxic Ischemic Encephalopathy Receiving Hypothermia

  2013cites this paper
• Computerized advice on drug dosage to improve prescribing practice.

  2013cites this paper
• Optimizing Antibiotic Pharmacodynamics for Clinical Practice

  2013cites this paper
• Approaches for dosage individualisation in critically ill patients

  2013cites this paper
• Clinical pharmacist impact on care, length of stay, and cost in pediatric cystic fibrosis (CF) patients

  2013cites this paper
• Antimicrobial Treatment of Febrile Neutropenia: Pharmacokinetic–Pharmacodynamic Considerations

  2013cites this paper
• An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration

  2012cites this paper
• Immediate Post‐Administration Safety of Bolus Gentamicin

  2012cites this paper
• Continuous beta-lactam infusion in critically ill patients: the clinical evidence

  2012cites this paper
• Extended interval dosing of gentamicin in premature neonates ≤ 28‐week gestation

  2012cites this paper
• Antibiotic dosing in children in Europe: can we grade the evidence from pharmacokinetic/pharmacodynamic studies – and when is enough data enough?

  2012cites this paper
• An information campaign on aminoglycosides use during septic shock failed to improve the quality of care.

  2012cites this paper
• 14. Antimicrobial Agents

  2012cites this paper
• Effects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin.

  2011cites this paper
• Optimizing antimicrobial therapy in sepsis and septic shock.

  2011cites this paper
• CHAPTER 37 – Clinical Pharmacology of Anti-Infective Drugs

  2011cites this paper
• Adaptive resistance to cationic compounds in Pseudomonas aeruginosa.

  2011cites this paper
• Commentaries on ‘One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates’

  2011cites this paper
• A double-blind study of the efficacy and safety of multiple daily doses of amikacin versus one daily dose for children with perforated appendicitis in Costa Rica.

  2011cites this paper
• Population pharmacokinetics of amikacin in a Korean clinical population.

  2011cites this paper
• The Application of Proteomics to PK-PD Modeling and Simulation

  2011cites this paper
• Clinical Decision Support Improves Initial Dosing and Monitoring of Tobramycin and Amikacin

  2011cites this paper
• Antimicrobial activity of commonly used antibiotics and DNA fingerprint analysis of Pseudomonas aeruginosa obtained from clinical isolates and unchlorinated drinking water in Korea, 2010

  2011cites this paper
• Symposium Summaries

  2011cites this paper
• Appropriate Antibiotic Dosage Levels in the Treatment of Severe Sepsis and Septic Shock

  2011cites this paper
• Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity.

  2011cites this paper
• Effect of experimentally induced synovitis on amikacin concentrations after intravenous regional limb perfusion.

  2011cites this paper
• LESSONS LEARNED FROM A MEASLES OUTBREAK IN ANTWERP, BELGIUM: 2007–2008

  2011cites this paper
• Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a systematic review and meta-analysis.

  2011cites this paper
• Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

  2010cites this paper
• Impact of infusion method on amikacin serum levels in humans.

  2010cites this paper
• Some current issues in the pharmacokinetics/pharmacodynamics of antimicrobials in intensive care.

  2010cites this paper
• Drug administration and blood sampling for pharmacokinetic studies in pediatric cancer patients

  2009cites this paper
• Optimizing antimicrobial therapy in sepsis and septic shock.

  2009cites this paper
• Animal models of ventilator-associated pneumonia

  2009cites this paper
• Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.

  2009cites this paper
• Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis

  2009cites this paper
• Experimental pneumococcus infection in mice: correlation of bactericidal activity in vitro with the effect in vivo for gentamicin, netilmicin and tobramycin.

  2009cites this paper
• Pharmacokinetic Outcomes of a Simplified, Weight‐Based, Extended‐Interval Gentamicin Dosing Protocol in Critically Ill Neonates

  2009cites this paper
• Therapeutic Drug Monitoring of Aminoglycosides in Neonates

  2009cites this paper
• The Use of Extended-Interval Aminoglycoside Dosing Strategies for the Treatment of Moderate-to-Severe Infections Encountered in Critically Ill Surgical Patients

  2009cites this paper
• Suboptimal Aminoglycoside Dosing in Critically Ill Patients

  2008cites this paper
• Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults.

  2008cites this paper
• Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.

  2008cites this paper